Bear's post about Roth initiating got me to do some googling.  Came across some news about Juniper  Pharma.  Juniper also engaged Rothschild to enhance shareholder walue.

http://www.biotuesdays.com/briefs/2018/3/9/roth-doubles-juniper-pharma-pt-to-24

Juniper was later bought out at $11.50 per share. 

https://www.reuters.com/article/us-juniper-pharms-m-a-catalent/catalent-to-buy-juniper-pharmaceuticals-for-11-50-per-share-idUSKBN1JT0WL

Roth also prowides inwestment banking serwices.  Which gets me to wondering whether a Naz listing with a correpsonding underwritten secondary might be in the cards.